Author

Sebastian Scheinost

German Cancer Research Center

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Jennifer HüelleiniD· 2 shared Junyan LuiD· 2 shared Thorsten ZenziD· 2 shared Wolfgang K. HuberiD· 2 shared Alexander Jethwa· 1 shared Benedikt BrorsiD· 1 shared Birgit Burkhardt· 1 shared Caroline LohoffiD· 1 shared

Activity by Year

2018-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersSystems Biology

Jennifer HüelleinORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer pathway connectivity resolved by drug perturbation and RNA sequencing

Thi Huong Lan Do, Caroline Lohoff, Ferris Jung, Sandra Kummer, Marcel Fabian Pohly, Sebastian Scheinost, Jennifer Hüellein, Vladimı́r Beneš, Wolfgang K. Huber, Junyan Lu, Thorsten Zenz

The paper uses drug perturbations and RNA sequencing to map pathway connectivity in CLL, showing how genetic aberrations modulate drug responses and pathway interactions.

bioRxiv · Dec 20, 2025 · PreprintSystems Biology

MDM4 is an essential disease driver targeted by 1q gain in Burkitt lymphoma

Jennifer Hüllein, Mikołaj Słabicki, Maciej Rosolowski, Alexander Jethwa, Stefan Habringer, Katarzyna Tomska, Roma Kurilov, Junyan Lu, Sebastian Scheinost, Rabea Wagener, Zhiqin Huang, Marina Lukas, Olena Yavorska, Hanne Helferich, René Scholtysik, , Thorsten Zenz

This study identifies MDM4 as a critical target of 1q gain in TP53wt Burkitt lymphoma, showing its role in evading cell cycle arrest and highlighting its therapeutic potential.

bioRxiv · Apr 9, 2018 · PreprintCancer Biology